CD8A and neoplasm: Furthermore, by targeting both β-catenin and PD-L1 with a racemic supramolecular peptide, it is possible to increase the infiltration of CD8+ T cells at the tumour site, thereby increasing the efficacy of immunotherapy for HCC (100).